Ception Therapeutics
Emerging biopharmaceutical company which develops novel products to address unmet medical needs
Malvern, PA
NASDAQ: CEPH
Contact: Jeff Himawan
Acquisition
Acquired by: Cephalon, Inc.
Exit date: April 06, 2010
Case Study
Essex Woodlands made our investment in Ception based upon our belief that Ception’s antibody against interleukin 5 (anti-IL-5mAb) would eventually become both a clinical and commercial success. …
Learn More